Description
| Product Name | Format | CAT.No | Size |
| CK-MB Immunoinhibition | LS | BXC0451A | R1: 1 x 35ml R2: 10 x 2.5ml R3: 1 x 2ml |
| CK-MB Immunoinhibition | LS | BXC0451B | R1: 1 x 105ml R2: 10 x 10ml R3: 1 x 2ml |
| CK-MB Immunoinhibition | LS | BXC0451C | R1: 1 x 15ml R2: 2 x 2.5ml R3: 1 x 2ml |
| CK-MB Enzymatic UV | LS | BXC0452A | R1: 1 x 25ml R2: 1 x 5ml |
| CK-MB Enzymatic UV | LS | BXC0452B | R1: 2 x 25ml R2: 2 x 5ml |
| CK-MB Enzymatic UV | LS | BXC0452C | R1: 10 x 3ml R2: 1 x 6ml |
| CK-MB Enzymatic UV | LS | BXC0452T | R1: 2 X 50ml R2: 2 X 10ml |
| CK-MB 4+1 | LS | BXC0458A | R1: 1 x 20ml R2: 1 x 4ml |
| CK-MB 4+1 | LS | BXC0458B | R1: 2 x 20ml R2: 1 x 10ml |
Product Description
The Biorex Diagnostics CK-MB Assay is a ready-to-use reagent system for the quantitative determination of CK-MB in human serum and plasma, providing essential insight into cardiac muscle injury. CK-MB is an isoenzyme of creatine kinase predominantly found in cardiac tissue and is released into the bloodstream following myocardial damage. Measurement is widely used in the diagnosis and monitoring of myocardial ischaemia and acute myocardial infarction (AMI), as well as for assessing the extent of cardiac injury and response to treatment. Its relative specificity for cardiac muscle makes it a valuable biomarker in clinical cardiology.
Key Features
- Quantitative measurement in serum and plasma
- Clinically relevant for early diagnosis and monitoring of myocardial infarction and cardiac events
- Highly specific immunoinhibition or enzymatic method ensures accuracy and reproducibility
- Ready-to-use reagents simplify workflow and reduce preparation errors
- Compatible with automated analysers, kinetic assays, and manual laboratory methods
Benefits
The Biorex Assay delivers precise, reliable, and reproducible results, supporting diagnosis, patient monitoring, and research applications in cardiology and clinical biochemistry. Its high analytical specificity enables accurate detection of cardiac-related enzyme activity, assisting clinicians in differentiating cardiac injury from skeletal muscle damage. By providing consistent and dependable measurements, the assay supports timely clinical decision-making and effective management of patients with suspected or confirmed cardiac events.
This assay is particularly valuable in hospital laboratories, emergency departments, cardiology units, and clinical chemistry settings where rapid evaluation of cardiac biomarkers is required. Its ready-to-use format streamlines workflow, reduces pre-analytical variability, and ensures consistent performance across different laboratory environments. Compatibility with automated analysers allows seamless integration into routine testing platforms, supporting efficient, high-throughput analysis while maintaining accuracy and reliability.
In addition to clinical diagnostics, the Biorex Assay supports research into cardiac injury mechanisms, biomarker development, and cardiovascular disease, making it an essential tool for advancing understanding of myocardial damage and improving patient outcomes.
Contact Us for more information.